Generate Biomedicines Surges Over 20% as Post-IPO Lock-Up Set to Expire

Published Aug 25, 03:32 PM UTC

Shares of Generate Biomedicines Inc (NASDAQ:GENB) surged over 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period on Wednesday. The lock-up expiration will allow company insiders, early investors, and major shareholders to sell shares from the $400 million IPO that included 25 million shares. Such expirations often bring volatility and higher trading volume. Generate is a clinical-stage generative biology company founded in 2018, using machine learning and biological engineering to design new therapeutics for hard-to-treat conditions. Its platform combines computational design with large-scale biological experimentation to create optimized therapies across multiple therapeutic areas.